Brought to you by 
AC Immune grosses CHF21mm with private financing
03 Jun 2005
Executive Summary
AC Immune (develops therapeutics for Alzheimer's disease and cancer) has grossed CHF21mm ($17.5mm) with its Series B venture round to new and existing institutional and private investors. (Two-thirds of the financing came from new investors.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AC Immune grosses CHF21mm with private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice